Experts predict a test measuring p-tau217 in blood plasma may become a standard screening tool for Alzheimer’s disease in ...

Microglial activity appears to determine when amyloid becomes biologically significant, reshaping how clinicians interpret ...

A multi-species synbiotic supplement has led to measurable improvements in weight, metabolic control and cardiovascular risk ...

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...

This population-based study used plasma pTau217 to estimate how common Alzheimer’s disease neuropathological changes are across age and cognitive status in a Norwegian community cohort. Prevalence ...

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...

New Australian research has identified simultaneous abnormalities across multiple biological systems in people with myalgic ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

Rare case shows a man living virus free for years after stopping treatment, raising new questions about how the immune system ...

Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and ...

From GLP-1 weight-loss drugs and mRNA cancer vaccines to longevity science and regenerative medicine, 2025 marked a decisive ...

A Macquarie University–led study has identified coordinated abnormalities in cellular energy, immune function and blood ...